Eli Lilly's Tirzepatide Study Targets Adolescents with Obesity and Comorbidities
Eli Lilly is conducting a study to evaluate tirzepatide's effects on weight and cardiovascular risk in adolescents with obesity.
Asset / Drug
Drug and asset intelligence for Tirzepatide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
GLP-1 Agonist
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.